NSE: GLAND | BSE: 543245

Mid-range Performer

Download real time

1715.80 0.70 (0.04%)

34.28% Gain from 52W Low

61,135 NSE+BSE Volume

NSE 02 Jan, 2026 3:31 PM (IST)

28,268.9

Market Cap

High in industry

Beta 1Year

Very Low volatility

Gland Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAND, BSE:543245 Gland Pharma Ltd.

Search Inside the pdf :

Gland Pharma Ltd.

04 Nov 2025

1715.80

0.04%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We revise our rating from HOLD to BUY

Gland Pharma Ltd. is trading below its 50 day SMA of 1778.7

Gland Pharma Ltd.

04 Nov 2025

1715.80

0.04%

In-line revenue; margin miss transient

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) delivered in-line revenue in 2QFY26. However, EBITDA/PAT came in below our expectations by 9%/11%. A lowerthan-expected share of milestone income and lower tech transfer/CMO business in ROW markets impacted 2QFY26 performance.

Number of FII/FPI investors increased from 212 to 260 in Sep 2025 qtr.

Gland Pharma Ltd.

04 Nov 2025

1715.80

0.04%

Gland Pharma

Buy: Gland Pharma Ltd.

ICICI Direct

About the stock: Gland Pharma is one of the largest generic injectable-focused Along with its partners, Gland owns 1,748 products registrations globally of which ~490 in US, Europe, Canada, Australia, and New Zealand, ~73 in...

Number of FII/FPI investors increased from 212 to 260 in Sep 2025 qtr.

Gland Pharma Ltd.

06 Aug 2025

1715.80

0.04%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We maintain our HOLD rating on the stock with a target price of Rs 1,950/share.

Number of FII/FPI investors increased from 212 to 260 in Sep 2025 qtr.

Gland Pharma Ltd.

06 Aug 2025

1715.80

0.04%

Strong margin gain boosts PAT by 50% YoY

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) posted revenue in line with our estimate in 1QFY26. However, EBITDA/PAT exceeded our estimates (13%/16% beat).

Gland Pharma Ltd. has an average target of 2250.00 from 3 brokers.

Gland Pharma Ltd.

04 Feb 2025

1715.80

0.04%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We maintain our HOLD rating with a target price of Rs 1,580, implying an upside potential of 4%, valuing the company at a PE of 20x for FY27.

Gland Pharma Ltd. is trading below its 50 day SMA of 1778.7

Gland Pharma Ltd.

03 Feb 2025, 12:00AM

1715.80

0.04%

New launches and higher milestone income drive margins

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (Gland) delivered a better-than-expected operating performance for the quarter. While revenue came in line, product mix and a higher share of milestone income led to better-than-expected margins in the base business.

Number of FII/FPI investors increased from 212 to 260 in Sep 2025 qtr.

Gland Pharma Ltd.

05 Nov 2024

1715.80

0.04%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

we maintain our HOLD rating with a target price of 1,760, implying an upside potential of ~9.4%, valuing the company at a PE of 26x for FY26.

Gland Pharma Ltd. has an average target of 2250.00 from 3 brokers.

Gland Pharma Ltd.

07 Aug 2024

1715.80

0.04%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We have Hold on the stock

Gland Pharma Ltd. is trading below its 50 day SMA of 1778.7

Gland Pharma Ltd.

06 Aug 2024

1715.80

0.04%

Lower milestone income and ROW sales hurt earnings

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) reported a miss on its 1QFY25 earnings, largely due to lower milestone income for the quarter. Further, postponement of the off-take of products by European customers hit 1QFY25 performance.

Gland Pharma Ltd. is trading below its 50 day SMA of 1778.7

VOTE: Is Gland Pharma Ltd. worth buying?

215 Votes:

Buy 80.93%

Sell 9.3%

Hold 9.77%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf